关于提请股东大会授权董事会以简易程序向 特定对象发行股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"或"药石科技"）根据战略 发展需要，为进一步提升公司的核心竞争力和技术创新水平，更好的实现公司未 来发展战略目标，根据《上市公司证券发行注册管理办法》、《深圳证券交易所 上市公司证券发行上市审核规则》、《深圳证券交易所上市公司证券发行与承销 业务实施细则》等相关规定，公司董事会于2024年4月23日召开第三届董事会第 三十次会议，审议通过了《关于提请股东大会授权董事会办理以简易程序向特定 对象发行股票相关事宜的议案》，同意董事会提请股东大会授权董事会以简易程 序向特定对象发行融资总额不超过人民币3亿元且不超过最近一年末净资产20% 的股票，授权期限为2023年年度股东大会审议通过之日起至2024年年度股东大会 召开之日止。上述事项尚需公司2023年年度股东大会审议通过。现将具体情况公 告如下： | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2024-032 | | --- | --- | ...

关于本报告 数说 2023 走进药石科技 01 02 04 | ESG 管理 | 12 | | --- | --- | | ESG 管理体系 | 12 | | 利益相关方沟通 | 14 | | 实质性议题分析 | 15 | | 联合国可持续发展目标（SDGs）回应 | 16 | 年度专题 | 绿色化学，构筑可持续未来 | 18 | | --- | --- | | 以绿色可持续发展为导向 | 20 | | 以持续优化为路径 | 24 | | 以赋能行业创新为己任 | 26 | 28 责任经营 01 | 公司治理 | 30 | | --- | --- | | 内控与风险管理 | 34 | | 商业道德 | 36 | | 信息安全 | 42 | | 隐私保护 | 44 | | 知识产权保护 | 45 | 附录 106 02 | 携手并进 | 46 | | --- | --- | | 创新赋能 | 48 | | 质量管理 | 52 | | 客户体验 | 56 | | 可持续供应链 | 59 | | 行业合作 | 60 | 04 | 和谐共融 | 78 | | --- | --- | | 赋能员工 | 80 | | 职 ...

Financial Performance - The company's operating revenue for 2023 was ¥1,725,203,986.49, an increase of 8.18% compared to ¥1,594,699,978.41 in 2022[24]. - The net profit attributable to shareholders decreased by 37.19% to ¥197,360,947.76 from ¥314,223,824.02 in the previous year[24]. - The basic earnings per share fell by 37.34% to ¥0.99, down from ¥1.58 in 2022[24]. - The total assets at the end of 2023 were ¥5,104,032,178.39, reflecting a growth of 4.97% from ¥4,862,189,119.46 in 2022[24]. - The net cash flow from operating activities was ¥246,839,976.80, a slight increase of 0.09% compared to ¥246,608,762.55 in 2022[24]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was ¥176,044,097.89, down 33.81% from ¥265,972,288.46 in 2022[24]. - The weighted average return on equity decreased to 7.16% from 12.44% in the previous year, a decline of 5.28%[24]. - The company experienced a decline in net profit for the third quarter of 2023, reporting ¥40,155,270.39 compared to ¥56,135,029.49 in the second quarter[28]. - The company achieved revenue of 1.725 billion yuan, an increase of 8.18% year-on-year[64]. - The net profit attributable to shareholders decreased to 197 million yuan, a year-on-year decline of 37.19%[64]. - The total revenue for 2023 reached ¥1,725,203,986.49, representing an 8.18% increase compared to ¥1,594,699,978.41 in 2022[91]. Investment and Cash Management - The company plans to use up to CNY 50,000,000 of temporarily idle raised funds for cash management without affecting normal operations[118]. - The total investment amount for the reporting period was CNY 942,274,358.30, representing a 53.48% increase compared to CNY 613,950,404.97 in the same period last year[109]. - The company raised a net amount of RMB 928,090,177.20 from the issuance of shares, with actual usage of RMB 37,483,455.26 during the reporting period, and a cumulative usage of RMB 530,329,334.17 as of December 31, 2023[119]. - The company has completed the use of all funds raised from the issuance of convertible bonds in 2022[125]. - The company has utilized 40,103.10 million of temporarily idle raised funds for purchasing low-risk financial products as of December 31, 2023[125]. Research and Development - R&D expenses amounted to 169 million yuan, with a R&D expense ratio of 9.81%, maintaining a high level in the industry[64]. - The company synthesized over 6,000 new molecular building blocks during the reporting period[70]. - The company is focusing on the development of high-end injectable formulations, which have longer development cycles[127]. - The company aims to enhance its capabilities in drug development and commercialization through innovative chemical technologies and new drug molecule designs[100]. - The company is increasing R&D investment and expanding its business chain to enhance its technical and service capabilities, thereby improving market competitiveness[137]. Market and Industry Trends - In 2023, global pharmaceutical R&D spending reached $161 billion, with R&D investment accounting for 23.4% of sales revenue, an increase of 4.6 percentage points from 2022[35]. - The number of new drugs launched globally in 2023 was 69, a 10% increase from 2022, with over 40% classified as "first-in-class" therapies, primarily in oncology (30%) and neurology (17%)[35]. - Emerging biotech companies contributed to 56% of new drugs launched in 2023, highlighting their role as innovation engines in the pharmaceutical market[36]. - China's share of global clinical pipelines rose from 3% a decade ago to 28% in 2023, with over 30 new drugs launched annually for six consecutive years[37]. - The Chinese CDMO market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% over the next five years, double the global growth rate, increasing its share of the global market from 11% in 2021 to 16% by 2025[37]. Corporate Governance - The company has a governance structure that complies with legal requirements, ensuring effective decision-making and operational independence from its controlling shareholders[147]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[148]. - The company has established an independent financial department with specialized personnel, ensuring financial operations are separate from controlling shareholders[149]. - The company has a well-defined corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent management[149]. - The company has engaged in multiple investor communications, with 248 participants in April 2023 and 68 in October 2023, discussing its annual and quarterly performance[141]. Risk Management - The company faces potential risks including a decline in drug research market demand, changes in industry policies, intensified market competition, and quality control risks[3]. - The company emphasizes the importance of maintaining awareness of investment risks related to forward-looking statements in the annual report[3]. - The company actively tracks regulatory changes in the pharmaceutical industry to adjust its operational strategies accordingly, minimizing adverse impacts from policy shifts[138]. - The company has not experienced major safety or environmental incidents, but it continues to invest in environmental protection and safety production measures as its business scales[139]. Employee and Talent Management - The total number of employees at the end of the reporting period was 2,455, with 1,351 in the parent company and 1,104 in major subsidiaries[184]. - The company employed 1,492 technical personnel, representing approximately 60.8% of the total workforce[184]. - The company has a total of 119 employees with a doctoral degree, contributing to its strong technical capabilities[185]. - The company's compensation policy includes a fixed salary and a variable salary based on project progress and individual performance, ensuring internal fairness and external competitiveness[186]. - The company has designed both technical and management promotion channels to offer employees good career development opportunities[186]. Strategic Initiatives - The company is committed to optimizing operational costs and improving profitability through lean operations and effective resource allocation[136]. - The company plans to implement advanced technologies such as continuous flow chemistry and biocatalysis to reduce project costs and enhance market competitiveness[135]. - The company aims to leverage its experienced management team to drive innovation and operational efficiency in the coming years[156]. - The company anticipates continued growth in revenue and market share as it implements its strategic initiatives[156]. - The company is actively investing in new technologies to improve its product pipeline and meet evolving market demands[156].

Financial Performance - The company's revenue for Q1 2024 was ¥377,460,431.51, a decrease of 1.56% compared to ¥383,440,937.44 in the same period last year[6] - Net profit attributable to shareholders was ¥49,485,359.20, down 14.32% from ¥57,755,969.84 year-on-year[6] - Basic earnings per share decreased to ¥0.25, a decline of 13.79% from ¥0.29 in the previous year[6] - Total operating revenue for Q1 2024 was CNY 377,460,431.51, a decrease of 1.5% compared to CNY 383,440,937.44 in Q1 2023[22] - Net profit for Q1 2024 was CNY 49,485,359.20, down 14.3% from CNY 57,755,961.44 in the same period last year[23] - The total comprehensive income for the first quarter of 2024 was CNY 49,626,884.56, a decrease from CNY 56,505,995.48 in the same period last year, representing a decline of approximately 12.5%[24] Cash Flow - The net cash flow from operating activities was ¥55,330,257.73, down 26.24% from ¥75,015,353.97 in the same period last year[6] - The company's cash and cash equivalents were CNY 792,815,660.74, down from CNY 988,200,226.50, a decrease of approximately 19.7%[20] - Cash inflow from investment activities totaled CNY 478,661,207.44, significantly higher than CNY 119,249,255.06 in the previous year, marking an increase of about 301.5%[27] - The net cash flow from investment activities was CNY 68,930,043.73, a substantial improvement from a negative CNY 539,946,998.48 in the same period last year[27] - Cash and cash equivalents at the end of the period were CNY 440,098,278.17, down from CNY 820,190,549.66 at the end of the previous year, representing a decrease of approximately 46.4%[27] - Total cash outflow from operating activities was CNY 409,432,971.35, compared to CNY 352,108,930.74 in the previous year, indicating an increase of approximately 16.3%[27] - The company incurred a cash outflow of CNY 196,106,641.68 from financing activities, a significant increase from CNY 62,089,206.73 in the previous year, representing an increase of about 215.5%[27] Assets and Liabilities - Total assets at the end of the period were ¥4,962,143,722.24, a decrease of 2.78% from ¥5,104,032,178.39 at the end of the previous year[6] - Total liabilities decreased to CNY 2,086,964,595.18 from CNY 2,271,754,945.18, a reduction of about 8.1%[20] - The company’s long-term borrowings were CNY 47,740,277.77, a slight decrease from CNY 50,034,657.53[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 36,447, with no preferred shareholders[11] - The largest shareholder, Yang Minmin, holds 20.69% of shares, amounting to 41,307,019 shares, with 8,300,000 shares pledged[11] - The top 10 shareholders collectively hold a significant portion of the company's shares, with the largest holding being 20.69%[11] - The company reported a total of 5,756,792 shares held by Henan Hengtong Boyuan Venture Capital Partnership, accounting for 2.88% of total shares[12] Revenue Breakdown - Revenue from drug research stage products and services was CNY 85,365,502.77, accounting for 22.62% of total revenue, up 5.45% year-over-year[16] - Revenue from drug development and commercialization stage products and services was CNY 291,938,068.80, down 3.45% from the previous year[16] Operating Costs and Expenses - Total operating costs decreased to CNY 325,204,409.51 from CNY 344,985,836.29, reflecting a reduction of approximately 5.8%[22] - Research and development expenses were CNY 34,513,051.40, a decrease of 28.6% compared to CNY 48,393,224.73 in Q1 2023[23] - The company reported a gross profit margin of 13.8% for Q1 2024, compared to 10.0% in Q1 2023[22] Taxation - The company recorded a 54.13% increase in taxes and surcharges, amounting to ¥5,103,201.63, in line with the company's expanded scale[9] - The company experienced a 68.07% decrease in tax refunds received, totaling ¥9,329,340.32, due to reduced export tax rebates[10]

南京药石科技股份有限公司 审计报告 苏公 W[2024]A566 号 目 录 | 1、 | 审计报告 ………………………………………………1 | | --- | --- | | 2、 | 合并资产负债表………………………..………………5 | | 3、 | 合并利润表………………….………………………….7 | | 4、 | 合并现金流量表 ………………………………………9 | | 5、 | 合并所有者权益变动表..………………………………11 | | 6、 | 母公司资产负债表…………………….……………….17 | | 7、 | 母公司利润表…………………………………………..19 | | 8、 | 母公司现金流量表……………………………………..20 | | 9、 | 母公司所有者权益变动表………………………… 21 | | | 10、财务报表附注 …………………………………………27 | | | 11、事务所营业执照复印件 | | | 12、签字注册会计师资质证明复印件 | 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2024-030 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于使用部分暂时闲置募集资金及自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示 1、投资种类：拟在不影响募集资金投资项目建设和正常经营的前提下，利 用部分暂时闲置募集资金购买安全性高、流动性好、有保本约定的投资产品；利 用自有资金购买安全性高、流动性好、中低风险理财产品等。 2、投资金额：拟使用不超过人民币4.5亿元的暂时闲置募集资金、不超过9.5 亿元的自有资金，该投资额度在投资期限内可循环使用。 3、风险提示：尽管相关产品风险较低，但金融市场受宏观经济的影响较大， 不排除该项投资受到市场波动的影响，敬请投资者注意投资风险。 南京药石科技股份有限公司（以下简称"公司"或"药石科技"）于2024 年4月23日召开的第三届董事会第三十次会议、第三次监事会第十八次会议，审 议通过了《关于使用部分暂时闲置募集资金进行 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2024-023 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于公司续聘 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、根据财政部、国务院国资委、证监会印发的《国有企业、上市公司选聘 会计师事务所管理办法》（财会[2023]4 号）及公司《会计师事务所选聘制度》的 相关规定。公司对 2024 年年审会计师事务所进行了邀请招标，根据中标结果， 公证天业会计师事务所（特殊普通合伙）排名第一位，拟续聘公证天业会计师事 务所（特殊普通合伙）为公司 2024 年度审计机构。 2、公司董事会审计委员会、董事会、监事会对本次拟续聘会计师事务所不 存在异议，本议案尚需提交公司 2023 年度股东大会审议。 南京药石科技股份有限公司（以下简称"公司"或"药石科技"）于 2024 年 4 月 23 日召开的第三届董事会第三十次会议、第三届监事会第十八次会议，审 议通过了《关于公司聘 ...

| 证券代码：300725 | 证券简称：药石科技 公告编号：2024-031 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 南京药石科技股份有限公司 关于签订《股份回购及相关事宜的条款清单》暨关联交易公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 关联交易基本情况 南京药石科技股份有限公司（以下简称"公司"）的全资子公司 PharmaBlock (USA), Inc.（以下简称"美国药石"）拟与 Myrobalan Therapeutics Holding, Inc.（以 下简称"迈巴制药"或"标的公司"）签署《股份回购及相关事宜的条款清单》 （以下简称"《条款清单》"）。迈巴制药拟回购美国药石所持其全部股份（优先股、 普通股）。《条款清单》经各自决策程序批准生效后，美国药石与迈巴制药将签订 《股份回购协议》等正式协议。截至本公告披露日，公司董事长杨民民先生担任 迈巴制药董事职务，根据《深圳证券交易所创业板股票上市规则》规定，迈巴制 药为公司关联方，本次交易构成关联交易。 2024 年 4 月 23 日， ...

南京药石科技股份有限公司 内部控制鉴证报告 苏公 W[2024]E1191 号 Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 内部控制鉴证报告 苏公W[2024]E1191号 南京药石科技股份有限公司全体股东： 目 录 1、内部控制鉴证报告 ………………………………………1 2、2023年度内部控制自我评价报告…………...……………3 3、事务所营业执照复印件 4、事务所执业证书复印件 5、签字注册会计师资质证明复印件 公证天业会计师事务所（特殊普通合伙） 我们接受委托，对南京药石科技股份有限公司（以下简称"药石科技"）董事会 《关于内部控制的自我评价报告》涉及的2023年12月31日财务报告内部控制有效性 的认定进行了鉴证。 四、鉴证意见 我们认为，药石科 ...

南京药石科技股份有限公司 2023年度内部控制自我评价报告 南京药石科技股份有限公司全体股东： 南京药石科技股份有限公司（以下简称"公司"）董事会根据《企业内部 控制基本规范》《企业内部控制应用指引》和《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等文件要求（以下简称"企业内部控制规范体系"），结合本公司内 部控制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们认真 开展了公司治理及内部控制的自查工作，对公司截止至2023年12月31日（内部 控制评价报告基准日）的内部控制有效性进行了评价。2023年度内部控制自我 评价具体情况如下： 一、重要声明 公司建立与实施内部控制坚持"全面性原则、重要性原则、制衡性原则、 适应性原则和成本效益原则"，并考虑了以下基本要素：内部环境、风险与评 估、控制活动、信息与沟通、内部监督。 二、内部控制评价结论 截止内部控制评价报告基准日，公司不存在财务报告内部控制重大缺陷， 董事会认为，公司已按照企业内部控制规范体系和相关规定的要求在所有重大 方面保持了有效的财务报告内部控制。 截止内部控制评价报告基准日 ...